- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03377673
Right Ventricular and Pulmonary Artery Evaluation by CMR
Right Ventricular Geometry, Function, Morphology and Pulmonary Arterial Stiffness and Size Evaluation by Cardiac Magnetic Resonance
Pulmonary hypertension results in right ventricle dysfunction. Cardiac magnetic resonance derived RV ejection fraction is a prognostic value in this condition.
Right ventricular geometry, function, morphology as well as pulmonary arterial stiffness and size may be evaluated by cardiac magnetic resonance imaging and could have great importance in evaluation of pulmonary hypertension prognosis and outcomes.
Study Overview
Detailed Description
Pulmonary hypertension is defined as an increase in mean pulmonary artery pressure > 25 mmHg evaluated by right heart catheterisation. Over time increased pulmonary artery pressure eventually causes vascular remodelling and right ventricular dysfunction. The right and left ventricles interact sharing a common pericardial sac and interventricular septum. Frequently right ventricle dysfunction reflects clinical PH worsening.
The aim of this study was to assess the geometry, function and morphology of right ventricle and also pulmonary artery diameter and stiffness in pulmonary hypertension patients by cardiovascular magnetic resonance.
Patients are recruited from the Hospital of Lithuanian University of Health Sciences Kaunas clinics Pulmonary hypertension center.
Study inclusion criteria:
- Patient with diagnosed pulmonary hypertension
- RHC, 6MWT, echocardiography, NT-pro BNP, CMR performed in one month period.
- Patients who signed study informed consent form.
Study exclusion criteria:
- Coronary and valvular heart disease
- Atrial fibrillation
- Expressed shortness of breath
- Claustrophobia.
Suspected number of participants - 100.
Data Analysis Statistical analyses will be performed using SPSS 22.0 package (SPSS, Chicago, IL, USA). Continuous variables will be expressed as mean +/- standard deviation, skewed variables as median (interquartile range). Chi square test will be used for qualitative parameters. For continuous variables, differences between two groups will be compared using non-parametric Mann-Whitney U test. Relation between variables will be assessed using Spearman correlation coefficient. Univariate analysis of predictors for survival will be used. In order to assess minimally false negative and minimally false positive results with greatest accuracy, the method of ROC (Receiver Operating Characteristics) curve will be used. The optimal values will be separated out the different groups (survival/non-survival) with the highest accuracy (minimal false negative and false positive). Survival curves will be established by the Kaplan-Meier estimation method. Cox regression analysis will be used to identify independent predictor of outcomes. Two-tailed probability values at p<0,05 will be considered statistically significant.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Kaunas, Lithuania, LT44307
- LSMU
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient with diagnosed pulmonary hypertension
- RHC, 6MWT, echocardiography, NT-pro BNP, CMR performed in one month period.
- Patients who signed study informed consent form.
Exclusion Criteria:
- Coronary and valvular heart disease
- Atrial fibrillation
- Expressed shortness of breath
- Claustrophobia.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Right ventricle function and morphological changes in pulmonary hypertension patients during follow up
Time Frame: 2 years
|
Right ventricle function will be evaluated by CMR at base line and during follow up to find significant values for disease progression and prognosis
|
2 years
|
Right ventricle function and morphological changes in pulmonary hypertension patients during follow up
Time Frame: 2 years
|
Pulmonary artery will be evaluated by CMR at base line and during follow up to find significant values for disease progression and prognosis
|
2 years
|
Left ventricle function and mechanical changes in pulmonary hypertension patients during follow up
Time Frame: 2 years
|
Left ventricle function and mechanical changes will be evaluated by CMR and FT at base line and during follow up to find significant values for disease progression and prognosis
|
2 years
|
Right ventricle mechanical changes in pulmonary hypertension patients during follow up
Time Frame: 2 years
|
Right ventricle function and mechanical changes will be evaluated by FT at base line and during follow up to find significant values for disease progression and prognosis
|
2 years
|
Collaborators and Investigators
Investigators
- Study Director: Lina Padervinskiene, PhD, LSMU
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- no. BE-2-23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
Heidelberg UniversityMerck Sharp & Dohme LLCRecruitingChronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial HypertensionGermany
-
University of South FloridaWithdrawnPulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Idiopathic Pulmonary Arterial Hypertension | Primary Pulmonary HypertensionUnited States
-
BayerCompletedPrimary HypertensionChina
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Papworth Hospital NHS Foundation TrustMerck Sharp & Dohme LLCCompleted
-
National Taiwan University HospitalUnknownPulmonary HypertensionTaiwan
-
University of ZurichCompletedPulmonary Hypertension | Pulmonary Artery Hypertension | Chronic Thromboembolic Pulmonary HypertensionSwitzerland
Clinical Trials on CMR
-
Karolinska InstitutetSwedish Medical Research CouncilCompletedMyocardial InfarctionSweden
-
Xiang Guang-daCompletedType 2 DiabetesChina
-
University of ZurichETH ZurichRecruitingNon ST Elevation Myocardial Infarction | Myocarditis Acute | Takotsubo Cardiomyopathy | Spontaneous Coronary Artery Dissection | Myocardial Infarction With Non-Obstructive Coronary ArterySwitzerland
-
Brigham and Women's HospitalCompleted
-
Radboud University Medical CenterUnknownBreast Cancer | Cardiotoxicity | Chemotherapy Induced Systolic DysfunctionNetherlands
-
NHS National Waiting Times Centre BoardBritish Heart Foundation; University of Glasgow; Chief Scientist Office of the...RecruitingCoronary Artery Disease | Angina, Stable | Angina Pectoris | Microvascular Angina | Non-Obstructive Coronary Atherosclerosis | Small Vessel Cerebrovascular DiseaseUnited Kingdom
-
Heinrich-Heine University, DuesseldorfRecruiting
-
NYU Langone HealthRecruiting
-
University of MichiganPhilips Health CareTerminatedCardiomyopathiesUnited States
-
University of GöttingenDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)Completed